A Polygenic and Phenotypic Risk Prediction for Polycystic Ovary Syndrome Evaluated by Phenome-Wide Association StudiesYoonjung Yoonie Joo, Timothy D. Spector, Robert J. Carroll et al.|The Journal of Clinical Endocrinology & Metabolism|2020Cited by 64
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trialAmanda Vrselja, Susan R. Davis, Rod Baber et al.|The Lancet|2022Cited by 16